Innovent’s Sintbilo Lowers LDL-C About 65% in Phase 3 Trial
Innovent Biologics said in a November 8, 2026 announcement that its Phase 3 CREDIT-5 trial met its primary endpoint, with SINTBILO (tafolecimab) reducing low-density lipoprotein cholesterol (LDL-C) by up to 65.19% after 12 weeks as monotherapy. The company plans to submit a new-indication application to China’s National Medical Products Administration (NMPA), seeking first-line use without statins for a drug that is already commercialized and reimbursed in China. The randomized, double-blind…